Emtricitabine Patent Expiration

Emtricitabine is Used for treating HIV infection in adults. It was first introduced by Gilead Sciences Inc in its drug Emtriva on Jul 2, 2003. 3 different companies have introduced drugs containing Emtricitabine.


Emtricitabine Patents

Given below is the list of patents protecting Emtricitabine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Emtriva US6703396

(Pediatric)

Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers Sep 09, 2021

(Expired)

Gilead
Emtriva US6642245

(Pediatric)

Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane May 04, 2021

(Expired)

Gilead
Emtriva US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers Mar 09, 2021

(Expired)

Gilead
Emtriva US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane Nov 04, 2020

(Expired)

Gilead
Emtriva US5914331

(Pediatric)

Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane Jan 02, 2018

(Expired)

Gilead
Emtriva US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane Jul 02, 2017

(Expired)

Gilead
Emtriva US5814639

(Pediatric)

Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds Mar 29, 2016

(Expired)

Gilead
Emtriva US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds Sep 29, 2015

(Expired)

Gilead



Emtricitabine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Emtricitabine Generic API Manufacturers

Several generic applications have been filed for Emtricitabine. The first generic version for Emtricitabine was by Cipla Ltd and was approved on Jul 2, 2018. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Mar 15, 2023.

Given below is the list of companies who have filed for Emtricitabine generic, along with the locations of their manufacturing plants worldwide.


1. AUROBINDO PHARMA LTD

Aurobindo Pharma Ltd has filed for 1 generic for Emtricitabine. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG

capsule Prescription ORAL AB Mar 15, 2023


Manufacturing Plant Locations
New

Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.

Country City Firm Name
India
Medchal Aurobindo Pharma Ltd





2. CIPLA

Cipla Ltd has filed for 1 generic for Emtricitabine. Given below are the details of the strengths of this generic introduced by Cipla.

Strength Dosage Form Availability Application Pathway TE code Launch Date
200MG

capsule Prescription ORAL AB Jul 2, 2018


Manufacturing Plant Locations
New

Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.

Country City Firm Name
India
Bengaluru Cipla Limited
Bangalore Cipla Ltd.
Vasco Da Gama Cipla Limited
Pithampur, District Dhar Cipla Limited
Mumbai Cipla Limited
Raigad Cipla Limited
Kurkumbh Village, Dist. Pune Cipla, Ltd.